TAIWANESE HEALTH AND RESEARCH DELEGATION VISIT PARATUS CLINICAL TRIAL SITE IN CANBERRA Visit fosters greater collaboration and experience of clinical trial execution in public and private health settings best practice
With
Matt Clacy,
Founder & Chief Commercial Officer
Paratus Clinical
Dr Amber Leah,
Principal Investigator & Medical Director
Paratus Clinical
Professor Chun-Jen Huang,
Dean of Office of Human Research
Taipei Medical University & Taipei Municipal Wanfang Hospital
Taiwan
Professor Pin-Kuei Fu,
Director, Clinical Research Center
Taichung Veterans General Hospital
Taiwan
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Canberra | September 2025
In late August 2025, a Taiwanese delegation comprising government officials from the Taiwanese FDA, various governmental groups, and physicians and researchers from across Taiwan, visited Paratus Clinical’s trial site in Canberra. Their objective was to explore both the differences and similarities between the clinical research ecosystems of Taiwan and Australia.
Throughout the discussions, the delegation learned about the processes involved in initiating research, the regulatory hurdles that must be navigated, and the practicalities of conducting clinical trials in both public and private sectors.
Paratus Clinical specialises in a range of clinical trials, from Phase I to Phase III, including vaccine studies and treatments across primary care areas such as asthma, diabetes, and cardiometabolic health, as well as outpatient specialties like dermatology and oncology.
The conversations also addressed the distinctions between inpatient and outpatient care, focusing on startup timelines, regulatory requirements, and patient recruitment strategies. Notably, the delegation found a reassuring number of similarities in clinical practice between the two countries.
Matt Clacy, recognised the potential benefit of fostering greater collaboration between public and private sectors in Australia, a practice that is more prevalent in Taiwan and advantageous for patient care and the healthcare system overall.
Source: Written by AUDIENCED
You Might also like
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
Priming Australia for social prescribing
Social prescribing provides support in various areas of people’s lives, leading to increased confidence, improved navigation of systems, and enhanced friendships and trust in healthcare, while communities should be designed in an age-friendly way to prevent isolation.
In Part 1 of the Models of Care on Social Prescribing, Australian Health Journal spoke to 4 people advocating for social prescribing in Australia
-
AHW Exhibitor: Health Professionals Bank
Healthcare professionals recently had a new bank enter the market. Health Professionals Bank owned by Teachers Mutual Bank, commenced operations in February this year aiming to be a member owned bank that “Cares for those who care”. Exhibiting at Australian Healthcare Week in Sydney last week, General Manager Carolyn Murphy spoke with Australian Health Journal reporter, Anne Dao
Post Views: 2,337